Celcuity/$CELC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
- Ticker
- $CELC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 155
- Headquarters
- Minneapolis, United States
- Website
- www.celcuity.com
Celcuity Metrics
BasicAdvanced
$3.2B
-
-$4.72
0.13
-
Price and volume
Market cap
$3.2B
Beta
0.13
52-week high
$151.02
52-week low
$53.54
Average daily volume
1.6M
Financial strength
Current ratio
14.619
Quick ratio
13.941
Long term debt to equity
-10.195
Total debt to equity
-10.198
Interest coverage (TTM)
-11.94%
Profitability
EBITDA (TTM)
-242.929
Management effectiveness
Return on assets (TTM)
-25.27%
Return on equity (TTM)
-1,192.88%
Valuation
Price to book
-42.67
Price to tangible book (TTM)
-25.47
Price to free cash flow (TTM)
-13.23
Free cash flow yield (TTM)
-7.56%
Free cash flow per share (TTM)
-4.862
Growth
Earnings per share change (TTM)
28.45%
3-year earnings per share growth (CAGR)
19.73%
What the Analysts think about Celcuity
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Analyst projections of the future price of Celcuity stock.
Bulls say / Bears say
Early launch indicators suggest broad access: 78% of Celcuity’s top 36 strategic accounts had ordered the drug, while health plans covering 91% of US commercial and Medicare lives included it. REVTORPYK also gained a preferred Category 1 NCCN recommendation for the approved setting. (Celcuity)
The PIK3CA-mutant Phase 3 results fell short of some investors’ expectations: median progression-free survival was about 11 months, below the 14.6-month result in an earlier, much smaller study. The triplet also did not clearly outperform the doublet, leaving uncertainty over which regimen doctors will favour. (BioPharma Dive)
The triplet’s efficacy comes with a substantial treatment burden: reported Grade 3 or higher neutropenia affected 62.3% of patients and stomatitis 19.2%, and two treatment-related deaths occurred in the triplet group. These risks could complicate prescribing and patient management. (Medscape)
Celcuity’s cash burn and debt raise the execution stakes: it used $66.2 million of operating cash in the third quarter and reported a $73.3 million loss, while carrying about $754 million in convertible notes. Continued commercial and trial spending will need to translate into revenue to limit future financing or dilution risk. (Celcuity, SEC)
Data summarised monthly by Lightyear AI. Last updated on 12 Nov 2026.
Celcuity Financial Performance
Revenues and expenses
Celcuity Earnings Performance
Company profitability
Upcoming events
No upcoming events
Celcuity News
AllArticlesVideos
Funds containing Celcuity
Fund name | Fund size | $CELC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.09% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.09% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.